<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3005">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04769245</url>
  </required_header>
  <id_info>
    <org_study_id>Acibadem Healthcare Group</org_study_id>
    <nct_id>NCT04769245</nct_id>
  </id_info>
  <brief_title>The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection</brief_title>
  <official_title>The Effectiveness of ACB-IP 1.0 Universal Pathogen Free Concentrated Cocktail Convalescent Plasma in COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acibadem University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ac覺badem Labcell</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Acibadem University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pathogen-free, concentrated, pooled convalescent plasma has higher SARS-CoV2 antibody titers&#xD;
      and neutralizing antibody activities, without requiring blood group compatibility that allows&#xD;
      patient accessibility in a shorter time and has safe plasma characteristic.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy of SARS-CoV2 standard single donor convalescent plasma varied according to the&#xD;
      application time and most importantly the amount of antibody that is administered. Single&#xD;
      donor plasma has some drawbacks; such as the insufficient levels of neutralizing antibody&#xD;
      activities, the requirements of blood group compatibility, and the risk of infection&#xD;
      transmission. In this study, the efficacy and safety of pathogen inactivated,&#xD;
      isohemagglutinin-depleted (concentrated) and pooled convalescent plasma was investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>6 Months</time_frame>
    <description>A mortality rate is a measure of the frequency of occurrence of death in a defined population during a specified interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of Hospitalization</measure>
    <time_frame>6 Months</time_frame>
    <description>The average length of stay in hospitals (ALOS) is often used as an indicator of efficiency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side Effects</measure>
    <time_frame>6 Months</time_frame>
    <description>Problems that occur when treatment goes beyond the desired effect. Or problems that occur in addition to the desired therapeutic effect.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Single donor convalescent plasma</arm_group_label>
    <description>Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with single donor plasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACB- IP 1.0</arm_group_label>
    <description>Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with ACB- IP 1.0 pathogen-free concentrated cocktail convalescent plasma</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2&#xD;
        and/or radiologically confirmed pneumonia, were included in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are over the age of 60 or-&#xD;
&#xD;
          -  Between the ages of 18-60, serious comorbidities (cancer, COPD, cardiovascular&#xD;
             illness, hypertension, DM)&#xD;
&#xD;
          -  Clinically diagnose COVID-19 or radiological diagnosed COVID-19 pnemonia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple Organ Failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Ercument Oval覺, MD</last_name>
    <phone>+905325729174</phone>
    <email>ercument.ovali@acibadem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cansu Hemsinlioglu</last_name>
    <phone>+905356782771</phone>
    <email>chemsinlioglu@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ac覺badem Labcell Cellular Therapy Laboratories</name>
      <address>
        <city>Istanbul</city>
        <zip>34758</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ercument Oval覺</last_name>
      <phone>+905325729174</phone>
      <email>ercument.ovali@acibademlabcell.com.tr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acibadem Altunizade Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cansu Hemsinlioglu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

